share_log

CRISPR Therapeutics | 8-K: Current report

CRISPR Therapeutics | 8-K: Current report

CRISPR Therapeutics | 8-K:重大事件
美股sec公告 ·  05/23 08:20
Moomoo AI 已提取核心訊息
CRISPR Therapeutics AG announced the appointment of Julianne Bruno as the new Chief Operating Officer effective May 23, 2024. Bruno, who has been with the company since April 2019, previously served as Senior Vice President and Head of Programs & Portfolio Management. Her promotion follows a successful tenure overseeing the hemoglobinopathy partnership program with Vertex Pharmaceuticals and the company's immuno-oncology trials. Bruno's new employment agreement includes an annual salary of $460,000, eligibility for the company's annual bonus program with a target bonus of 45% of her base salary, and a one-time grant of 20,000 restricted stock units. The agreement also outlines terms for termination and provides for a six-month notice period, with provisions for a 12-month notice period and immediate vesting of equity awards in the event of a termination following a Change in Control. The company filed the full text of the Employment Agreement with the SEC as Exhibit 10.1.
CRISPR Therapeutics AG announced the appointment of Julianne Bruno as the new Chief Operating Officer effective May 23, 2024. Bruno, who has been with the company since April 2019, previously served as Senior Vice President and Head of Programs & Portfolio Management. Her promotion follows a successful tenure overseeing the hemoglobinopathy partnership program with Vertex Pharmaceuticals and the company's immuno-oncology trials. Bruno's new employment agreement includes an annual salary of $460,000, eligibility for the company's annual bonus program with a target bonus of 45% of her base salary, and a one-time grant of 20,000 restricted stock units. The agreement also outlines terms for termination and provides for a six-month notice period, with provisions for a 12-month notice period and immediate vesting of equity awards in the event of a termination following a Change in Control. The company filed the full text of the Employment Agreement with the SEC as Exhibit 10.1.
CRISPR Therapeutics AG宣佈任命朱麗安·布魯諾爲新任首席運營官,自2024年5月23日起生效。布魯諾自2019年4月起在公司工作,此前曾擔任高級副總裁兼項目與投資組合管理主管。她的晉升是在成功監督與Vertex Pharmicals的血紅蛋白病合作計劃以及該公司的免疫腫瘤學試驗之後獲得的。布魯諾的新僱傭協議包括46萬美元的年薪,有資格參加公司的年度獎金計劃,目標獎金爲其基本工資的45%,以及一次性發放20,000個限制性股票單位。該協議還概述了終止條款,並規定了六個月的通知期,其中規定了12個月的通知期,如果控制權變更後終止,則立即授予股權獎勵。該公司以附錄10.1的形式向美國證券交易委員會提交了僱傭協議的全文。
CRISPR Therapeutics AG宣佈任命朱麗安·布魯諾爲新任首席運營官,自2024年5月23日起生效。布魯諾自2019年4月起在公司工作,此前曾擔任高級副總裁兼項目與投資組合管理主管。她的晉升是在成功監督與Vertex Pharmicals的血紅蛋白病合作計劃以及該公司的免疫腫瘤學試驗之後獲得的。布魯諾的新僱傭協議包括46萬美元的年薪,有資格參加公司的年度獎金計劃,目標獎金爲其基本工資的45%,以及一次性發放20,000個限制性股票單位。該協議還概述了終止條款,並規定了六個月的通知期,其中規定了12個月的通知期,如果控制權變更後終止,則立即授予股權獎勵。該公司以附錄10.1的形式向美國證券交易委員會提交了僱傭協議的全文。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息